Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00627042 · ClinicalTrials.gov registry record · Phase 2
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00627042 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 42 participants.
The verdict
NCT00627042, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
Interventions
- BIOLOGICAL Ramucirumab (IMC-1121B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00627042
The ClinicalTrials.gov registry entry for NCT00627042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ramucirumab (IMC-1121B) is the first listed.
NCT00627042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00627042 about?
NCT00627042 is a clinical study titled "Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy". A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
What is the current status of trial NCT00627042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2008-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00627042?
The interventions under investigation include: Ramucirumab (IMC-1121B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00627042?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.